Plasma Catecholamine Measurement in the Diagnosis of Pheochromocytoma and Paraganglioma

Diagnostic Utility

Performance Compared with Metanephrines

Guideline Recommendations (Endocrine Society)

Practical Diagnostic Algorithm (Endocrine Society)

Biochemical Testing for Pheochromocytoma and Paraganglioma

Indications for 24‑hour Urinary Catecholamine Testing

• The 24‑hour urinary catecholamine assay is used primarily to biochemically diagnose pheochromocytoma and paraganglioma (PPGL) in patients with hypertension accompanied by episodic headaches, palpitations, or sweating. – Endocrine Society [​5]
• It is also indicated in individuals with hereditary PPGL‑predisposing syndromes such as SDH mutations, von Hippel‑Lindau disease, MEN 2, and neurofibromatosis 1. – Endocrine Society [​6][​5]

Diagnostic Performance Compared with Metanephrines

• In a series, urinary catecholamines showed a sensitivity of 47 %–74 %, whereas urinary fractionated metanephrines achieved 97 % sensitivity for detecting PPGL. – Endocrine Society [​5][​7]
• Because catecholamines are released intermittently from tumors, false‑negative results occur in 16 %–26 % of cases when catecholamines are used as the sole test. – Endocrine Society [​5]

Guideline Recommendations (Endocrine Society)

• The Endocrine Society strongly recommends urinary fractionated metanephrines rather than urinary catecholamines as the initial biochemical test for PPGL, citing superior continuous production of metanephrines within tumor cells. – Endocrine Society [​5][​7]

Practical Collection Considerations

• Measurement of urinary creatinine is required to confirm the completeness of the 24‑hour collection. – Endocrine Society [​5][​7]
• Incomplete urine collections are a frequent source of diagnostic error in catecholamine testing. – Endocrine Society [​5]

Preferred Alternative Tests

• Plasma free metanephrines: sensitivity ≈ 98.6 %, specificity ≈ 89.3 %. – Endocrine Society [​5][​7]
• Urinary fractionated metanephrines: sensitivity ≈ 97 %–100 %, specificity ≈ 94 %–98 %. – Endocrine Society [​5][​7]

Limitations and Clinical Pitfalls

• Do not rely solely on urinary catecholamines to exclude PPGL; a normal result does not rule out disease in the presence of high clinical suspicion. – Endocrine Society [​5]
• When suspicion remains high despite normal catecholamines, the guideline advises proceeding directly to urinary or plasma metanephrine testing. – Endocrine Society [​5][​7]

Plasma Free Metanephrines – First‑Line Biochemical Test for Suspected Pheochromocytoma

Diagnostic Accuracy

• Sensitivity: Plasma free metanephrines detect pheochromocytoma in 97‑99 % of cases, far exceeding the 47‑74 % sensitivity of 24‑hour urinary catecholamines. 8
• High‑risk cohort data: In a NIH study of > 800 patients, plasma free metanephrines maintained 97 % sensitivity even when compared with combinations of other biochemical tests. 9
• Specificity: Across multiple investigations, plasma free metanephrines show 89‑100 % specificity. 8
• Lenders 2002 study: Reported plasma free metanephrines sensitivity of 98.6 % versus urinary fractionated metanephrines sensitivity of 97.1 %. 8
• Discrimination (ROC‑AUC): Area under the curve for plasma free metanephrines ranges from 0.965 to 1.0, indicating near‑perfect test performance. 8
• Consistent validation: Fifteen independent studies have confirmed the high diagnostic accuracy of plasma free metanephrines for pheochromocytoma. 8

Biological Rationale

• Continuous production: Metanephrines are generated continuously inside tumor cells by catecholamine O‑methyltransferase, independent of episodic catecholamine release. 9
• Intermittent catecholamine secretion: Catecholamines are released sporadically via exocytosis, leading to false‑negative results when tumor secretion is low or intermittent. 9
• Specificity to chromaffin tumors: Sympathetic nerves lack the O‑methyltransferase enzyme, making metanephrines relatively specific markers of chromaffin‑cell neoplasms. 9

Guideline Recommendations (Endocrine Society, 2014)

• Strong recommendation (Grade A): Do not use plasma or urinary catecholamines as the initial biochemical test for suspected pheochromocytoma because of their markedly inferior sensitivity. 8
• Rationale: Maximizing diagnostic sensitivity is essential to avoid missing potentially lethal tumors. 10
• First‑line options: Use plasma free metanephrines (or urinary fractionated metanephrines) as the initial test. 8

Practical Testing Considerations

• Test ordering: Obtain plasma free metanephrines (both metanephrine and normetanephrine) as the first biochemical investigation. 8
• Analytical method: Employ liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) or LC with electrochemical detection; immunoassays underestimate concentrations and have lower sensitivity. 8
• Laboratory verification: Confirm that the laboratory uses LC‑MS/MS or LC‑electrochemical detection, as immunoassays are imprecise and substantially underestimate plasma metanephrine levels. 8
• Urine collection quality: If 24‑hour urine testing is required, measure urinary creatinine to verify collection completeness. 8

Common Pitfalls & Solutions

• Pitfall: Relying on urinary catecholamines alone to exclude pheochromocytoma.

  • Solution: Never use urinary catecholamines as a stand‑alone rule‑out test; a normal result does not exclude disease. 8

• Pitfall: Using immunoassays for plasma metanephrines.

  • Solution: Switch to LC‑MS/MS or LC‑electrochemical detection to avoid underestimation and improve precision. 8

• Pitfall: Incomplete 24‑hour urine collections.

  • Solution: Check urinary creatinine levels to ensure collection adequacy. 8

Guideline‑Recommended Use of Plasma Free Metanephrines for Pheochromocytoma Diagnosis

1. Guideline Recommendations (Endocrine Society, 2014)

• The Endocrine Society Clinical Practice Guideline designates plasma free metanephrines as the preferred first‑line biochemical test for pheochromocytoma, with urinary fractionated metanephrines accepted only when proper plasma collection cannot be performed. Strong recommendation (Class I). 11

2. When Plasma Testing Is Not Feasible – Recommended Alternative

• Urinary fractionated metanephrines should be used when the patient cannot be positioned supine for ≥30 minutes before phlebotomy. 12
• They are also advised when phlebotomy services routinely draw blood in the seated position, which markedly raises false‑positive rates. Moderate recommendation. 13
• If referral to a center experienced in supine plasma collection is impossible, urinary testing is the acceptable substitute. 11

3. Critical Pre‑analytical Requirements for Plasma Free Metanephrines

• Patient positioning: The patient must lie fully supine for at least 30 minutes before the blood draw; reference intervals must be derived from supine samples. Strong recommendation. 12
• Effect of seated sampling: Drawing blood while seated induces sympathetic activation and can produce false‑positive results; any positive result obtained in this manner must be repeated after a supine collection. Strong recommendation. 13

4. Medication and Physiological Interferences

• Tricyclic antidepressants interfere with the interpretation of both plasma and urinary metanephrine measurements. Moderate recommendation to discontinue or account for use. 14
• Acetaminophen, mesalamine, and sulfasalazine can cause analytical interference with LC‑electrochemical detection methods; laboratories should use LC‑MS/MS when these agents are present. Strong recommendation for assay selection. 14
• Extreme physiological stress (e.g., intensive‑care settings) may elevate metanephrine levels independent of tumor secretion, potentially leading to false‑positive results. Moderate recommendation to interpret with caution. 14
• Fasting requirement: Fasting is necessary only when the assay includes 3‑methoxytyramine (dopamine metabolite); otherwise, fasting is not required. Strong recommendation. 12

5. Clinical Algorithm for Test Selection (Endocrine Society)

• Step 2 – Proper plasma collection: Ensure the patient has been supine ≥30 minutes before phlebotomy and verify that the laboratory employs LC‑MS/MS or LC‑electrochemical detection. Strong recommendation. 12
• Step 3 – If supine plasma collection impossible: Order a 24‑hour urinary fractionated metanephrine panel, confirm collection completeness with urinary creatinine, and provide dietary restriction instructions. Strong recommendation. 13
• Step 4 – Borderline elevations: Repeat the plasma test after a supine draw or perform a clonidine suppression test to differentiate true positives from false‑positives. Moderate recommendation. 15

6. Practical Advantages of Plasma Testing (Endocrine Society)

• Plasma free metanephrine measurement avoids the many collection‑dependent errors inherent to 24‑hour urine collection (patient compliance, storage, incomplete collection), making it more reliable in routine clinical practice. Strong recommendation. 11